ライフサイエンスコーパス: opioid

1 c efficacy should guide development of safer opioids.

2 istics and any use and new persistent use of opioids.

3 rformed will help prevent overprescribing of opioids.

4 the burden of chronic pain and dependence on opioids.

5 egion are responsible for its sensitivity to opioids.

6 their role in modulating motivation to take opioids.

7 The analysis was limited to approved opioids.

8 pioid use and a lower likelihood of using no opioids.

9 gy, physiology, and behavior in the study of opioids.

10 about vulnerable populations at high risk of opioid abuse and death.

11 With opioid abuse-related deaths rising at unprecedented rate

12 y over 200 years ago, the molecular basis of opioid action has remained the subject of intense inquir

13 knowing which specific peptidase(s) control opioid actions in the relevant neural circuit and how th

14 t opioid users have elevated infection risk, opioids activate innate immune cells, and opioids attenu

15 Opioid addiction and overdose are at record levels in th

16 system as a mechanism for the development of opioid addiction and/or mood disorder.

17 (buprenorphine, methadone) is effective for opioid addiction but does not eliminate opioid use in al

18 Opioid addiction has been declared a public health emerg

19 esents an effective therapeutic approach for opioid addiction, it is not as widely used as needed.

20 relapse prevention maintenance treatment for opioid addiction.

21 he control group consumed significantly more opioids after discharge(median 121.3MME vs 23.5MME, P <

22 of IMV patients received a prescription for opioids after hospital discharge, and 2.6% met criteria

23 s [MME] of >=50/day and >=90/day), number of opioid agents (>=2), and duration (>=30 days) among thos

24 PWID), it is crucial to effectively scale-up opioid agonist therapy (OAT), such as methadone or bupre

25 ciated factors in a cohort of PWID receiving opioid agonist therapy (OAT).

26 Methadone is a synthetic opioid agonist with notoriously unique properties, such

27 Maintenance treatment with opioid agonists (buprenorphine, methadone) is effective

28 sts nor antagonists, 5 participants who used opioid agonists (without antagonists) had lower microbio

29 microbiota characteristics related to use of opioid agonists and antagonists among people receiving o

30 f hallucinogen studies, the effects of kappa-opioid agonists on human brain function are not well-und

31 It has been demonstrated that opioid agonists that preferentially act at mu-opioid rec

32 ropriate indications for the prescription of opioids among retina specialists.

33 Most women with MBC require opioid analgesia within the first month after diagnosis.

34 which RGS proteins modulate the efficacy of opioid analgesics in a brain region- and agonist-selecti

35 eir pharmacological profile against existing opioid analgesics in assays not confounded by limited si

36 labeled as IDRIs if discharge codes included opioid and/or amphetamine misuse.

37 d will be a refreshing take on reading about opioids and disease.

38 e sustained inhibitory actions of endogenous opioids and DOPr agonists.

39 nts who were given moderate-to-high doses of opioids and expected to remain alive and ventilated for

40 ne predominated; many PWID concurrently used opioids and methamphetamine or cocaine.

41 g of the beneficial and maladaptive roles of opioids and opioid receptor signaling.

42 iew recent studies on the mechanisms linking opioids and sleep.

43 hways normally depend on the binding between opioids and their receptors.

44 jor reductions in in-hospital consumption of opioids, and reduced pain, compared to conventional mana

45 uch as the benzomorphans, and the classic mu opioid antagonists, naloxone, naltrexone, and nalmefene.

46 Unused opioids are also subject to misuse and diversion, and th

47 Opioids are commonly used as analgesics for severe pain,

48 Opioids are critical in pain management; however, the of

49 Opioids are frequently coprescribed with psychotropic me

50 This challenges the paradigm that extended opioids are needed for effective postoperative pain mana

51 n a preponderance of data demonstrating that opioids are overprescribed after surgery.

52 bstruction, resuscitation care for suspected opioid-associated emergencies, drowning, and harm from C

53 ety of Retina Specialists members prescribed opioids at a rate (1.5%) lower than the national mean of

54 k, opioids activate innate immune cells, and opioids attenuate inflammation in murine T cell-mediated

55 opioids in primary care and does not include opioids available over the counter or prescribed in hosp

56 Here, we argue that published claims of opioid bias based on application of the operational mode

57 Most efforts have been focused on targeting opioids, but there is little information about vulnerabl

58 Secondary outcomes were postoperative opioid consumption, pain (0- 10-point scale; 0: no pain;

59 (PEU) films that controllably deliver a non-opioid COX-2 inhibitor, etoricoxib, in vivo and in vitro

60 e, we developed a rat model of incubation of opioid craving after electric barrier-induced voluntary

61 hey have a continuing role in addressing the opioid crisis and Ending the HIV Epidemic.

62 t Tennessee, an area heavily impacted by the opioid crisis and IDU.

63 use, misuse, and addiction, but because the opioid crisis includes multiple substances, the opioid s

64 Interventions to address the U.S. opioid crisis primarily target opioid use, misuse, and a

65 d States is in the midst of an unprecedented opioid crisis with increasing injection drug use (IDU)-r

66 With the nation's focus on the opioid crisis, methamphetamine has made a comeback, pote

67 terminal pain has been a major driver of the opioid crisis, together with the availability, overpresc

68 To deal successfully with the opioid crisis, we need to discover novel analgesics whos

69 , have been reported in conjunction with the opioid crisis.

70 re how RWHAP can best respond to the growing opioid crisis.

71 IE group shows the downstream effects of the opioid crisis.

72 younger age, and shorter duration of OST and opioid dependence.

73 tegies to reduce/eliminate HIV reservoirs in opioid dependent PLWH.IMPORTANCE Identification and clea

74 few years provides hope for new, efficacious opioids devoid of the side effects that have made them t

75 As with other drugs or pharmaceuticals, opioids differ in their rewarding or analgesic effects d

76 ired effects than most clinically prescribed opioids, DOPr is a promising alternative therapeutic tar

77 The powerful analgesic effects of opioid drugs have captivated the interest of physicians

78 scientists for millennia, and the ability of opioid drugs to produce serious undesired effects has be

79 ger with an interactive electronic registry, opioid education, academic detailing and access to addic

80 this methodology may be employed to predict opioid effects on other cancer types and to personalize

81 ion that beta-arrestin2 mediates deleterious opioid effects.

82 es necessary to affect the trajectory of the opioid epidemic and associated infections.

83 In the United States, the opioid epidemic has increased the number of overdose dea

84 The current opioid epidemic is one of the most severe public health

85 The current opioid epidemic necessitates a better understanding of h

86 The "Opioid Epidemic" has generated a drive for a deeper unde

87 een a significant contributor to the current opioid epidemic.

88 Our study indicates that opioid-evoked adaptations in brain function and behavior

89 tance of screening patients for preoperative opioid exposure and creating risk mitigation strategies

90 e what is known of the mechanisms underlying opioid exposure and sleep.

91 Preoperative opioid exposure was also associated with higher risk of

92 hlights four new areas of exploration in the opioid field.

93 ry, 41% of patients had nonchronic, periodic opioid fills.

94 oximately 25% of patients who are prescribed opioids for chronic pain misuse them, and 5 to 10% devel

95 of Health for deaths caused by prescription opioids from 2010-2017 to analyze the spatiotemporal dyn

96 Opioid guidelines are inherently flawed by the anchoring

97 ies suggested that people with HIV who abuse opioids had higher reservoirs in CNS than the lymphoid s

98 rimentally, such apparently G protein-biased opioids have been shown to exhibit low intrinsic efficac

99 However, how opioid impacts the immune system is still barely charact

100 Results strongly implicate opioids in gregarious song and suggest that endogenous o

101 his study was limited to patients prescribed opioids in primary care and does not include opioids ava

102 gregarious song and suggest that endogenous opioids in the mPOA may facilitate song by influencing a

103 xpected burden of IE among people who inject opioids in the U.S. is large.

104 e same opioid receptors triggered by classic opioids-in particular the u-opioid receptor (MOR).

105 Across outbreaks, injection of opioids (including fentanyl) or methamphetamine predomin

106 First, mu-opioids induce a long-lasting suppression of inhibitory

107 nic effects of SNC80 were lost in a model of opioid induced hyperalgesia/medication overuse headache

108 demonstrates that in the nucleus accumbens, opioid-induced excitatory synaptic plasticity involves p

109 We have established an in vitro model of opioid-induced hyperalgesic priming (OIHP), in male rats

110 based method to perform unbiased analyses of opioid-induced MOR internalization in the rat substantia

111 common cause of opioid overdose and death is opioid-induced respiratory depression (OIRD), a life-thr

112 During follow-up, opioid injecting (odds ratio [OR], 0.95; 95% confidence

113 in FQ peptide (N/OFQ; 500 nM), an endogenous opioid-like peptide, normalized GABA transmission in HA

114 stitution of this lead-contaminated opium by Opioid Maintenance Therapy (OMT)-prescribed opium tinctu

115 is little evidence regarding coordination of opioid management and best practices for patients on lon

116 ith a bird's intrinsic reward state and with opioid markers in the medial preoptic nucleus (mPOA).

117 membrane potential) decrease sensitivity to opioid-mediated inhibition of cAMP and promote hyperacti

118 ulating the activity of circuits involved in opioid-mediated physiology and behaviors.

119 ricular thalamus (PVT) outputs to contextual opioid memories.

120 Prescription opioid misuse is an ongoing crisis and a risk factor for

121 rug overdose deaths (largely attributable to opioid misuse) in the United States have grown exponenti

122 ing is warranted in order to curb iatrogenic opioid morbidity and mortality.

123 bserved, when compared with nociceptors from opioid naive rats.

124 ioid user," was defined as a patient who was opioid-naive before surgery and subsequently filled at l

125 Data regarding the types of care for which opioid-naive patients are provided initial opioid prescr

126 We identified 15,657 opioid-naive patients who underwent a range of surgical

127 ed 16,292,018 opioid prescriptions filled by opioid-naive patients.

128 which GABA neurotransmission is regulated by opioid neuropeptides, including dynorphin.

129 us macaque (RM) model to study the impact of opioids on HIV reservoirs.

130 Between 1997 and 2018, the FDA approved opioids on the basis of pivotal trials of short or inter

131 Women prescribed opioids only were more likely to have an antepartum hosp

132 Among 958 980 pregnant women, 10% received opioids only, 6% psychotropics only, and 2% opioids with

133 s, intestinal secretagogues, drugs acting on opioid or 5-HT receptors, or minimally absorbed antibiot

134 h >18 months of Part D coverage and no prior opioid or gabapentinoid use between 18 and 7 months befo

135 Whether use of opioids or gabapentinoids (also used to treat pain in pa

136 The most common cause of opioid overdose and death is opioid-induced respiratory

137 o analyze the spatiotemporal dynamics of the opioid overdose epidemic.

138 intertwined human immunodeficiency virus and opioid overdose epidemics.

139 e spatial associations between georeferenced opioid overdose event (OOE) data from emergency medical

140 ption (up to 8 h), as compared to the KGOP01 opioid parent compound.

141 us peptide activity, and genetic knockout of opioid peptide precursors.

142 Here, we show that opioid peptide receptors, GPCRs that mediate highly sens

143 Endogenous opioid peptides in the amygdala regulate many of our beh

144 Instead, the opioid peptides play complex and overlapping roles in a

145 n the identification of the first endogenous opioid peptides.

146 ng of sex differences in immune function and opioid pharmacokinetic and pharmacodynamic parameters, s

147 ies have described collecting data regarding opioid prescribing and patient-reported use in a cohort

148 However, whether and how the prescriber's opioid prescribing behavior impacts persistent opioid us

149 Florida's opioid prescribing reform substantially reduced drug ove

150 regions, practices, and prescribers vary in opioid prescribing whilst accounting for case mix.

151 The key exposure was the historical opioid-prescribing pattern of a patient's most responsib

152 6 types of behavioral strategies to decrease opioid prescription at discharge after surgery.

153 e surgery and subsequently filled at least 1 opioid prescription between 60 and 180 days after surger

154 Opioid prescription was higher among women prescribed ps

155 January 2012 and October 2015 and filled an opioid prescription within 30 days postoperatively.

156 ription overall increased from 4.4% to 7.6%, opioid prescription without coprescription of psychotrop

157 Opioid prescription, dosage thresholds (morphine milligr

158 stent opioid use included receiving a larger opioid prescription, having more comorbidities, having a

159 2016, with 66% of members writing at least 1 opioid prescription.

160 Opioid prescriptions after surgery are effective for pai

161 h opioid-naive patients are provided initial opioid prescriptions are limited.

162 of intervention seemed effective in reducing opioid prescriptions at discharge after surgery without

163 The frequency of opioid prescriptions decreased to 3.0% (81/2736) after i

164 718 analyzed lives, we identified 16,292,018 opioid prescriptions filled by opioid-naive patients.

165 On average, members wrote 11 opioid prescriptions per year.

166 ines, 103 of the 115 (89.6%) preintervention opioid prescriptions would not have adhered to the guide

167 922 (1.5%) patients continued filling opioids prescriptions for at least 3 months after surger

168 Among 6732 children, 68% were prescribed opioids (range = 1-65 d, median = 4 d, IQR = 3-5 d).

169 ssociated with higher odds of post-procedure opioid receipt.

170 Delta opioid receptor (DOR) agonists have been identified as a

171 es of mu-opioid receptor (MOR) agonist/delta-opioid receptor (DOR) antagonist bicyclic core peptidomi

172 rk has established a role for both the Kappa Opioid Receptor (KOR) and its endogenous ligand dynorphi

173 al member of the receptor-inactivating kappa opioid receptor (KOR) antagonists, norbinaltorphimine (n

174 We evaluated the occupancy of the kappa opioid receptor (KOR) by naltrexone measured with [(11)C

175 verted a metabolically unstable series of mu-opioid receptor (MOR) agonist/delta-opioid receptor (DOR

176 In this study, we found that the mu opioid receptor (MOR) gene, Oprm1, is highly expressed i

177 gered by classic opioids-in particular the u-opioid receptor (MOR).

178 We propose that G protein-biased mu opioid receptor agonists, currently in development as an

179 MCAM (0.1-0.32 mg/kg) or the opioid receptor antagonist naltrexone (0.001-0.032 mg/kg

180 A combination of olanzapine and the opioid receptor antagonist samidorphan is under developm

181 Methocinnamox (MCAM), a mu opioid receptor antagonist with a long duration of actio

182 esics whose mechanisms do not involve the mu opioid receptor but that have high analgesic potency and

183 ich depends on subregional differences in mu-opioid receptor coupling to the downstream cAMP/PKA intr

184 Although ultra-high-resolution opioid receptor crystal structures have revealed a speci

185 stress reactivity together with spinal/brain opioid receptor expression were also measured.

186 The mu-opioid receptor gene undergoes extensive alternative spl

187 Allelic differences in the human mu opioid receptor gene, notably the A118G single nucleotid

188 258747 blocked the internalization of the mu-opioid receptor most efficaciously because it has the ab

189 eficial and maladaptive roles of opioids and opioid receptor signaling.

190 nagement; however, the often-forgotten delta opioid receptor system has been identified as a novel th

191 t is well known that activation of the kappa opioid receptor system modulates negative affect and dys

192 g mouse TRPC4beta and the G(i/o) -coupled mu opioid receptor, we investigated the role of intracellul

193 ssion and function of the full-length 7TM mu-opioid receptor.

194 fficacy-delimited conformations of the kappa opioid receptor.

195 hich we confirm by locally eliminating the u-Opioid receptor.

196 genetic manipulations to alter or remove mu-opioid receptors (MORs) with anatomic and cell type spec

197 rate thought to be caused by stimulation of opioid receptors in the inspiratory-generating regions o

198 na speciosa (kratom), had higher affinity at opioid receptors than at adrenergic receptors while the

199 pioid agonists that preferentially act at mu-opioid receptors to activate G protein signaling over be

200 oid reduction of pain depends on coupling of opioid receptors to Galphai/o family members.

201 r in vivo (in animals), using antagonists of opioid receptors to infer endogenous peptide activity, a

202 nd drug cravings, despite acting on the same opioid receptors triggered by classic opioids-in particu

203 amic (i.e., pseudoirreversible binding to mu opioid receptors) and not pharmacokinetic factors play a

204 g of the fundamental signaling mechanisms of opioid receptors.

205 uitment) of 22 peptides at each of the three opioid receptors.

206 Opioid reduction of pain depends on coupling of opioid r

207 ve music significantly reduced postoperative opioid requirement (pooled SMD -0.31 [95% CI -0.45 to -0

208 acaine plane block would result in decreased opioid requirements compared to placebo in the first 72

209 ch Conference has played in the evolution of opioid research and emphasizes how technological advance

210 sis, we show that in male rats SCI decreases opioid responsiveness in vitro within a specific subset

211 rons in the SNr play more important roles in opioid reward and relapse than MORs on VTA GABA neurons.

212 s on VTA GABA neurons.SIGNIFICANCE STATEMENT Opioid reward has long been believed to be mediated by i

213 These findings suggest that opioid reward is more likely mediated by stimulation of

214 ation-related pathway critical to relapse to opioid seeking after voluntary abstinence.SIGNIFICANCE S

215 pathways similarly regulate reinstatement of opioid-seeking remains unknown, as is their role in modu

216 ur data reveal the PAG as a source of highly opioid-sensitive GABAergic afferents and support the ide

217 of Ca(V)2.2 channel isoforms with increased opioid sensitivity in mice.

218 ve therapy option and is based upon antibody-opioid sequestering to block brain entry.

219 hancement in palatability was independent of opioid signaling and not recapitulated by NAcSh or dopam

220 , and food intake, understanding the role of opioid signaling within the OFC is fundamental for a mec

221 Both insulin and serotonin stimulated opioid signaling, whereas NHR-69 suppressed opioid signa

222 opioid signaling, whereas NHR-69 suppressed opioid signaling.

223 A major component ERAS pathways is opioid-sparing analgesia; however, the effect on postope

224 NSAIDs have analgesic, opioid-sparing, and anti-inflammatory effects.

225 oid crisis includes multiple substances, the opioid specificity of interventions may limit their abil

226 r, these results suggest that presynaptic mu-opioid stimulation of local PV(+) interneurons induces a

227 and youth unemployment, Gini coefficient, or opioid substitution therapy coverage provision at the co

228 Opioids, such as morphine and fentanyl, are widely used

229 Interventions are needed to address the HCV-opioid syndemic in this region.

230 evidence for dysregulation of the endogenous opioid system as a mechanism for the development of opio

231 , but recent studies now implicate the kappa opioid system in the modulation of negative affect assoc

232 both the orbitofrontal cortex (OFC) and the opioid system regulate reward, motivation, and food inta

233 for improved understanding of the endogenous opioid system that will help in developing more effectiv

234 Here, we hypothesized that the u-opioid system-extensively implicated in placebo effects,

235 Using recently established models of opioid-taking and -seeking behaviors, we showed that sys

236 physical injuries resulting from trauma with opioids, the ability of opioid treatments to subsequentl

237 and best practices for patients on long-term opioid therapy patients following surgery.

238 rts should center on decreasing exposures to opioids through a physician-lead response.

239 The abilities of opioids to activate downstream signaling pathways normal

240 MRGPRX2 responds to various drugs, including opioids, to elicit pseudoallergic reactions, but whether

241 Here, we present conclusive evidence that opioid tolerance occurs independently of MOR internaliza

242 (PET) radioligand, to investigate endogenous opioid tone in AD for the first time.

243 95% CI, 1.10-1.36), and the availability of opioid treatment (aHR, 1.26; 95% CI, 1.01-1.57) were all

244 ing from trauma with opioids, the ability of opioid treatments to subsequently modify PTSD-related be

245 The development of new persistent opioid use after surgery is a common complication, howev

246 is study examined the trends and patterns of opioid use among working-age, privately insured patients

247 rger prescriptions were associated with more opioid use and a lower likelihood of using no opioids.

248 s completing DAA therapy with active illicit opioid use at intake, 14 (46.4%) engaged in opioid use d

249 Patients with nonchronic, periodic opioid use before surgery are vulnerable to persistent p

250 Going forward, identifying preoperative opioid use can inform surgeon prescribing and care coord

251 Opioid use disorder (OUD) is a chronic, relapsing condit

252 opioid use at intake, 14 (46.4%) engaged in opioid use disorder (OUD) treatment during therapy, and

253 Patients with opioid use disorder (OUD) who are hospitalized for serio

254 sting it could be an effective treatment for opioid use disorder (OUD).

255 With these challenges facing opioid use disorder treatments immunopharmacotherapy is

256 ffectiveness of current medications to treat opioid use disorder, there is still a high rate of relap

257 the development of tolerance and can lead to opioid use disorder.

258 toward the goals of preventing and treating opioid use disorder.

259 ic pain misuse them, and 5 to 10% develop an opioid use disorder.

260 omising strategy to reduce the prevalence of opioid use disorders (OUDs) and to prevent toxicity from

261 spite the large comorbidity between PTSD and opioid use disorders, as well as the common treatment of

262 sion to examine likelihood of second fill by opioid use group.

263 However, patients with persistent opioid use had sustained increases in spending by approx

264 for opioid addiction but does not eliminate opioid use in all patients.

265 alyze the relationship between pretransplant opioid use in lung transplant candidates and retransplan

266 owever, the effect on postoperative pain and opioid use in patients undergoing lung resection is unkn

267 Other risk factors for new persistent opioid use included receiving a larger opioid prescripti

268 ioid prescribing behavior impacts persistent opioid use is unclear.

269 Opioid use kills tens of thousands of Americans each yea

270 Patients without persistent opioid use returned to baseline health care spending wit

271 Persistent opioid use was also associated with older age, Medicaid

272 derwent inpatient procedures, new persistent opioid use was associated with health care spending (+$2

273 erwent outpatient procedures, new persistent opioid use was similarly correlated with higher health c

274 ence suggested increased risk for persistent opioid use with past or current substance use disorder (

275 surgery is feasible, and resulted in reduced opioid use, and healthcare utilization, with no differen

276 ng injection equipment, injection frequency, opioid use, general drug use, and participation in drug

277 ress the U.S. opioid crisis primarily target opioid use, misuse, and addiction, but because the opioi

278 Secondary outcomes included total inpatient opioid use, pain scores determined using a 100 mm visual

279 over multiple time points and new persistent opioid use.

280 r, 1.5% of patients developed new persistent opioid use.

281 ikely to be listed due to active alcohol and opioid use.

282 s cohort, 8103 patients developed persistent opioid use.

283 Primary outcome was overall days of opioid use.

284 d-forward interaction between poor sleep and opioid use.

285 g of the cyclical feedback between sleep and opioid use.

286 cy for preventing chronic pain and long-term opioid use.

287 y are vulnerable to persistent postoperative opioid use.

288 ry outcome was "new persistent postoperative opioid user," was defined as a patient who was opioid-na

289 tory and immunosuppressive activity, in that opioid users have elevated infection risk, opioids activ

290 logical treatment to prevent relapse in male opioid users.

291 ce voluntarily consume both cannabinoids and opioids via gelatin, and that cannabinoids provide long-

292 When opioids were prescribed, the mean OME decreased from 93

293 The relatively high efficacy of opioids, which have associated risks of addiction, toler

294 chotropics decreased from 11.9% to 8.4%, and opioids with coprescription decreased from 28.1% to 22.0

295 opioids only, 6% psychotropics only, and 2% opioids with coprescription of psychotropics.

296 of success in the design of completely novel opioids with unique efficacies.

297 Codeine was the most commonly prescribed opioid, with use increasing 5-fold from 2006 to 2017, re

298 e of abuse, and no evidence of dependence or opioid withdrawal by AEs or objective measures.

299 e potency and efficacy, whereas the onset of opioid withdrawal is prevented.

300 e opposing functional effects produced by mu-opioids within the OFC.SIGNIFICANCE STATEMENT Considerin